A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Conditions
Corpus Uteri
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
- Trial withYale Cancer Center
- Start Date02/24/2020
- End Date02/29/2024
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Anamika Katoch, MD
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- Carrie Fijal
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Elena Ratner, MD
- Francesca Montanari, MD
- Gary Altwerger, MD
- Gulden Menderes, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Harold, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Kristen Hoxie
- M. Sung Lee, MD
- Masoud Azodi, MD
- Michael Cohenuram, MD
- Natalia Buza, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Peter Schwartz, MD
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephanie Cerrito
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Susan Rabinowe, MD
- Vaagn Andikyan, MD
- Victor Chang, MD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated07/15/2021
- Study HIC#2000026850